Risk & Screening

A careful assessment begins with uncertainty, not eligibility. A centre should ask about medical history, current symptoms, past cardiac events, fainting, seizures, liver disease, pregnancy status, psychiatric history, substance use, and every prescribed, over-the-counter, and non-prescribed drug. This page’s broader stage-by-stage safety framework is useful only when those questions lead to an actual decision path rather than a generic intake conversation.

Cardiac risk deserves particular attention because ibogaine and its metabolites have been associated with changes to cardiac electrical activity. The U.S. Food and Drug Administration describes a prolonged QT interval as a finding that can raise the risk of dangerous rhythm disturbances; its discussion of QT prolongation and abnormal heart rhythms illustrates why medication review and an ECG cannot be treated as administrative details.

Screening should distinguish a stated history from records that can be checked. A responsible process explains which findings may make participation unsafe, which require outside clinical evaluation, and which circumstances call for postponement. It should not imply that a short questionnaire can establish safety.

Objective screening commonly includes an ECG, blood pressure and pulse assessment, and laboratory work that can identify electrolyte disturbance and assess liver function. Depending on history and risk, further testing or outside evaluation may be necessary. The point is not a fixed checklist; it is whether a centre can explain what each result means, who has reviewed it, and how a concerning result changes the plan.

A test result is useful only when someone can say what threshold would change the plan.

There are important evidence limits. Ibogaine remains investigational, and a centre’s testing routine should not be presented as proof that serious harm has been eliminated. For context on the substance itself, the overview of ibogaine’s pharmacology and legal status notes the unsettled and variable landscape around its use.

A medication list should include names, doses, timing, recent changes, supplements, alcohol, and other substances. Opioid exposure is especially important to clarify: stopping, continuing, or changing opioids can carry its own risks, and a centre should not reduce that discussion to a universal taper instruction. Drugs that can prolong QT or affect cardiac rhythm also need careful review.

Any plan involving medicines should identify who is responsible for advising on changes, how withdrawal or destabilization will be handled, and when the individual’s usual prescriber needs to be involved. The questions used to compare care-setting safeguards can help keep medication, monitoring, and escalation details in the same conversation rather than treating them as separate promises.

Psychiatric screening matters as well. Current suicidal thinking, a history of psychosis or mania, severe anxiety, poor sleep, recent crisis, or limited support may require additional assessment, delay, or a different care pathway. The National Institute of Mental Health describes suicide prevention as a matter of recognizing warning signs and connecting people to appropriate support; no informal intake can substitute for a credible safety response when acute risk is present.

• Ask whether the centre screens for current suicide risk, psychosis risk, mania, and recent psychiatric instability.
• Ask how it documents concurrent medications and the rationale for every proposed change.
• Ask what happens if a screening disclosure indicates that proceeding is unsafe or requires outside care.

Informed consent should be a process with documentation, not a signature used to shift responsibility. It should describe known and unknown risks, evidence gaps, alternatives, the limits of the setting, monitoring arrangements, transfer triggers, and what emergency support is realistically available. A useful review also asks whether the person was given time to ask questions and whether uncertainty was described plainly.

An emergency plan should name the operational steps: what deterioration looks like, who assesses it, what equipment and monitoring are available, how emergency services are contacted, and how a transfer is coordinated. Families and prospective clients can use the independent ibogaine treatment safety resource as one starting point for comparing claims against the records and explanations a centre is willing to provide.

Before leaving, a responsible centre should be able to provide transferable records: screening findings, medication and substance information, consent documentation, a monitoring summary, complications or interventions if any, discharge instructions, and a way for another clinician to understand what occurred. Documentation cannot make an intervention safe, but its absence makes later care and accountability harder.